Cochrane · systematic review · CD006628
Zotepine versus other atypical antipsychotics for schizophrenia
Subramanian, S, Rummel‐Kluge, C, Hunger, H, et al. · Cochrane Database of Systematic Reviews · 2010 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
9
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 5 · 35.7%Very low 8 · 57.1%Low 1 · 7.1%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
ZOTEPINE versus CLOZAPINE for schizophrenia (all short term outcomes)
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mental state: Average score (BPRS total, high=poor) Brief Psychiatric Rating Scale. Scale from: 0 to 126. ZOTEPINE vs CLOZAPINE | no estimate extracted | 1 study · 59 participants | Very low Downgraded: risk of bias, indirectness, publication bias |
Global state: No clinically important response (as defined by the original studies) clinical assessment ZOTEPINE vs CLOZAPINE | RR 8.23 [1.14, 59.17] | 1 study · 59 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Adverse effects: Extrapyramidal effects ‐ use of antiparkinson medication ZOTEPINE vs CLOZAPINE | RR 20.96 [2.89, 151.9] | 2 studies · 116 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Behaviour: No clinically important response (as defined by the original studies) ZOTEPINE vs CLOZAPINE | no estimate extracted | 0 studies · 0 participants | Ungraded |
ZOTEPINE versus RISPERIDONE for schizophrenia (all short term outcomes)
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mental state: Average endpoint score (BPRS total, high=poor) ‐ vs 4mg Risperidone Scale from: 0 to 129. ZOTEPINE vs RISPERIDONE | no estimate extracted | 1 study · 40 participants | Very low Downgraded: risk of bias, imprecision, indirectness, publication bias |
Mental state: Average endpoint score (BPRS total, high=poor) ‐ vs 8 mg Risperidone Scale from: 0 to 129. ZOTEPINE vs RISPERIDONE | no estimate extracted | 1 study · 40 participants | Very low Downgraded: risk of bias, imprecision, indirectness, publication bias |
Global state: No clinically important response (as defined by the original studies) ZOTEPINE vs RISPERIDONE | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse effects: Extrapyramidal effects ‐ use of antiparkinson medication ‐ vs 4mg risperidone ZOTEPINE vs RISPERIDONE | RR 6 [0.79, 45.42] | 1 study · 40 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Adverse effects: Extrapyramidal effects ‐ use of antiparkinson medication ‐ vs 8mg risperidone ZOTEPINE vs RISPERIDONE | RR 3 [0.69, 13.12] | 1 study · 40 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Behaviour: No clinically important response (as defined by the original studies) ZOTEPINE vs RISPERIDONE | no estimate extracted | 0 studies · 0 participants | Ungraded |
ZOTEPINE versus REMOXIPRIDE for schizophrenia (all short term outcomes)
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mental state: Average endpoint score (BPRS total, high=poor) Scale from: 0 to 129. ZOTEPINE vs REMOXIPRIDE | no estimate extracted | 1 study · 58 participants | Very low Downgraded: risk of bias, imprecision, indirectness, publication bias |
Global state: No clinically important response (as defined by the original studies) ZOTEPINE vs REMOXIPRIDE | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse effects: Extrapyramidal effects ‐ use of antiparkinson medication ZOTEPINE vs REMOXIPRIDE | RR 0.97 [0.41, 2.29] | 1 study · 49 participants | Low Downgraded: risk of bias, publication bias |
Behaviour: No clinically important response (as defined by the original studies) ZOTEPINE vs REMOXIPRIDE | no estimate extracted | 0 studies · 0 participants | Ungraded |